Elevated triglycerides and low levels of high-density lipoprotein as markers of disease activity in association with up-regulation of the tumor necrosis factor alpha/tumor necrosis factor receptor system in systemic lupus erythematosus.
about
Regulation of Adaptive Immunity in Health and Disease by Cholesterol MetabolismIdentification of MAMDC1 as a candidate susceptibility gene for systemic lupus erythematosus (SLE)Factors associated with metabolic syndrome in patients with systemic lupus erythematosus from Puerto Rico.Graded effects of proteinuria on HDL structure in nephrotic ratsDyslipidaemia in rheumatological autoimmune diseasesDecreased high-density lipoprotein cholesterol levels in polyarticular juvenile idiopathic arthritis.Bone Loss Triggered by the Cytokine Network in Inflammatory Autoimmune Diseases.Cardiovascular events in early RA are a result of inflammatory burden and traditional risk factors: a five year prospective study.Systemic lupus erythematosus in a multiethnic US cohort (LUMINA): XXIV. Cytotoxic treatment is an additional risk factor for the development of symptomatic osteonecrosis in lupus patients: results of a nested matched case-control study.Three functional variants of IFN regulatory factor 5 (IRF5) define risk and protective haplotypes for human lupus.The TNFalpha locus is altered in monocytes from patients with systemic lupus erythematosus.Lack of nitric oxide synthases increases lipoprotein immune complex deposition in the aorta and elevates plasma sphingolipid levels in lupusSLE, atherosclerosis and cardiovascular disease.Longer durations of antitumour necrosis factor treatment are associated with reduced risk of cardiovascular events in patients with rheumatoid arthritisAccelerated atherosclerosis, arterial thromboembolism, and preventive strategies in systemic lupus erythematosus.Therapy Insight: osteoporosis and osteonecrosis in systemic lupus erythematosus.Role of resistin as a marker of inflammation in systemic lupus erythematosus.Gluten-free vegan diet induces decreased LDL and oxidized LDL levels and raised atheroprotective natural antibodies against phosphorylcholine in patients with rheumatoid arthritis: a randomized study.Identification of definitive serum biomarkers associated with disease activity in primary Sjögren's syndromeManagement of dyslipidemia in children and adolescents with systemic lupus erythematosus.Apolipoprotein A-I gene transfer exerts immunomodulatory effects and reduces vascular inflammation and fibrosis in ob/ob mice.Systemic lupus erythematosus and cardiovascular disease.Myeloid dendritic cells correlate with clinical response whereas plasmacytoid dendritic cells impact autoantibody development in rheumatoid arthritis patients treated with infliximab.Simvastatin treatment ameliorates autoimmune disease associated with accelerated atherosclerosis in a murine lupus model.Microparticles in the blood of patients with systemic lupus erythematosus (SLE): phenotypic characterization and clinical associations.Normalizing glycosphingolipids restores function in CD4+ T cells from lupus patients.High-density lipoprotein affects antigen presentation by interfering with lipid raft: a promising anti-atherogenic strategy.HDL and immunomodulation: an emerging role of HDL against atherosclerosis.Pathogenesis of cutaneous lupus erythematosus: common and different features in distinct subsets.HDL in innate and adaptive immunity.Serum soluble tumour necrosis factor receptor-2 (sTNFR2) as a biomarker of kidney tissue damage and long-term renal outcome in lupus nephritis.IFN-γ induces lipogenesis in mouse mesangial cells via the JAK2/STAT1 pathway.Prevalence, risk factors and outcome of digital gangrene in 2684 lupus patients.Systemic lupus erythematosus in a multiethnic US cohort (LUMINA). XXIII. Baseline predictors of vascular events.Triglyceride Levels and Fracture Risk in Midlife Women: Study of Women's Health Across the Nation (SWAN).The frequency of high/moderate lipoprotein risk factor for coronary artery disease is significant in juvenile-onset systemic lupus erythematosus.Lack of subclinical myocardial ischaemia in Mexican patients with systemic lupus erythematosus without traditional risk factors for coronary artery disease.Platelet-activating factor-acetylhydrolase and other novel risk and protective factors for cardiovascular disease in systemic lupus erythematosus.Anti-lipoprotein lipase antibodies: a new player in the complex atherosclerotic process in systemic lupus erythematosus?Dysregulations in circulating sphingolipids associate with disease activity indices in female patients with systemic lupus erythematosus: a cross-sectional study.
P2860
Q28083961-F0189BAE-6B44-466F-8B89-0DA6C4F3F040Q30973856-B4360E6C-F821-4A72-BBA8-2DF1FD9D56F9Q33379277-48092CDE-D70E-412A-8078-F27668AAC163Q34586564-F907825C-6E95-41C4-BD99-933CD8C1BE22Q35029916-99785B93-5EA3-42CB-A91F-F6910BD3F424Q35188363-E3DA0765-77E2-444A-B2F0-6A9824739B07Q35614331-30395C8B-CA4E-496B-B81A-7ABD83295A17Q35617716-84CE3FF8-9DC7-4E5C-84E9-A327359E7D5BQ35637240-F1461F6E-EFC9-4B12-A79F-D0968CB4D870Q35741943-0936FD71-2532-45A8-B9C7-156D5D4239FEQ35867539-DB05D212-C7B8-4E44-B7B0-DF21A3F7B050Q36101077-BC04B457-7AD2-442D-A31E-265BE1E04650Q36135534-6929CE3A-18F6-43E5-8545-0272E12827F1Q36182351-8FAB9409-513B-400A-93BA-86DC8E0311FAQ36461116-79BDF989-CDD3-4F62-8569-4E46E45BEBD7Q36611056-C5BFF135-1EB4-4BC3-ABE5-AEF9AEADB91BQ36641497-71F06824-FE5C-4E8B-9F4B-9F14D7ED35AFQ36757006-D2694461-BFF6-4532-95E1-24C1C352AE04Q36903959-812257F7-4049-4787-A477-B094AAD5DBE1Q36915663-0379C5CC-F7ED-42AC-96C3-D403407E7DADQ37145156-77F35265-C2F4-4D19-8F77-000A1AA9C6B7Q37167995-BD9C1FC4-95A5-4E05-AA3F-9C1623780695Q37270902-FEDC8C0F-60E3-42DF-98F6-06BDE3620B44Q37362915-1EFF863A-2329-4DB3-8998-DD90B87DD713Q37363894-985BD307-4FDC-4741-9708-22261ED1CF24Q37524224-5B4C2537-8EDC-4EDC-9B98-C1EABAA815AEQ37670939-14D0C9AA-007C-49E6-B50D-231F46F97E94Q37672264-15293EA1-CF95-4D07-BA3B-7583770F0CE0Q37778642-8EE345C9-54BA-47D4-B836-16DB249B6482Q38220759-DD8492FF-19A3-404C-B660-61408376879BQ39101016-1EE77C1B-FCE8-4974-BDCE-8F9BC894CE57Q39194928-E45DA306-0979-4496-B23B-B692598901B9Q39900850-95A7629C-D636-4147-8712-8757A06071A5Q40461525-0447CF84-6987-4DC1-9044-50B80A264B38Q40705019-98054A94-5CB5-4E5F-883B-EB9D4734913FQ41946752-471F536B-DC78-42B9-B22A-1B24375AB14AQ44112580-5EDBCA11-8DAF-4FD4-8C66-DB881E97D4FDQ45085322-7B5AE1C9-37BC-43BA-9E65-0D7B4791066FQ45141249-AD7E2449-4BBB-4FB9-9317-24AFDBB2D906Q47876362-F12C34DB-BEFC-4696-8443-A589737D226A
P2860
Elevated triglycerides and low levels of high-density lipoprotein as markers of disease activity in association with up-regulation of the tumor necrosis factor alpha/tumor necrosis factor receptor system in systemic lupus erythematosus.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年学术文章
@wuu
2003年学术文章
@zh
2003年学术文章
@zh-cn
2003年学术文章
@zh-hans
2003年学术文章
@zh-my
2003年学术文章
@zh-sg
2003年學術文章
@yue
2003年學術文章
@zh-hant
name
Elevated triglycerides and low ...... systemic lupus erythematosus.
@en
Elevated triglycerides and low ...... systemic lupus erythematosus.
@nl
type
label
Elevated triglycerides and low ...... systemic lupus erythematosus.
@en
Elevated triglycerides and low ...... systemic lupus erythematosus.
@nl
prefLabel
Elevated triglycerides and low ...... systemic lupus erythematosus.
@en
Elevated triglycerides and low ...... systemic lupus erythematosus.
@nl
P2093
P2860
P50
P356
P1476
Elevated triglycerides and low ...... systemic lupus erythematosus.
@en
P2093
Guo-Zhong Fei
Iva Gunnarsson
Johan Frostegård
P2860
P304
P356
10.1002/ART.11264
P577
2003-09-01T00:00:00Z